Biovail shells out upfront fee of $500,000. Biovail gained access to Depomed’s AcuForm™ drug delivery technology for the development of up to two products. Biovail may select these products from an ...

MENLO PARK, Calif., Aug. 27, 2012 /PRNewswire/ -- Depomed, Inc. (Nasdaq:DEPO) today announced that Janssen Pharmaceuticals, Inc., has licensed rights to Depomed's Acuform gastric retentive drug ...

Up to $64M in milestone payments could be realized. Covidien has licensed worldwide rights to utilize Depomed’s AcuForm™ gastric retentive drug delivery technology for the exclusive development of ...

Depomed Licenses Acuform® Patents to Janssen Pharmaceuticals, Inc. MENLO PARK, Calif., Aug. 27, 2012 /PRNewswire/ -- Depomed, Inc. (Nasdaq: DEPO) today announced that Janssen Pharmaceuticals, Inc., ...

Depomed, Inc. (NASDAQ: DEPO) announced today that it has received another $500,000 milestone payment after the first formulation that is being developed under its worldwide license agreement with ...

MENLO PARK, Calif.--(BUSINESS WIRE)--Depomed, Inc. (NASDAQ:DEPO) today announced that in its Phase 1 pharmacokinetic study in Parkinson’s patients, DM-1992, Depomed’s investigative novel gastric ...

MENLO PARK, Calif., Oct 12, 2009 -- Depomed, Inc. (NASDAQ:DEPO) announced today top-line results from the BREEZE 1 and 2 Phase 3 clinical trials evaluating the safety and efficacy of SeradaTM, an ...